OncoMatch/Clinical Trials/NCT06734572

18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study

Is NCT06734572 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 18F-FAPIBiotin for malignant neoplasm.

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06734572Data as of May 2026

Treatment: 18F-FAPIBiotin — As a new dual targeting PET radiotracer, 18F-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 18F-FAPI-Biotin in patients with various types of cancer and compared them with the results of 18F-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 18F-FAPI.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify